The APLP2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the APLP2 gene. Derived from the A-549 human lung adenocarcinoma epithelial cell line, this product offers a heterogeneous pool of cells with targeted disruptions in the APLP2 locus, enabling robust investigation of APLP2-mediated cellular processes. The polyclonal format mitigates clonal selection artifacts and preserves population-level biological variability, making it ideal for assays that require bulk cellular responses.
The A-549 cell line is a well-characterized model of human lung adenocarcinoma, originally established from a 58-year-old Caucasian male. These adherent epithelial cells harbor KRAS mutations and wild-type EGFR, reflecting a clinically relevant genetic background for lung cancer research. A-549 cells are widely utilized to study oncogenic signaling, drug response, and metastatic properties, providing a physiologically appropriate host for APLP2 knockout in the context of non-small cell lung carcinoma.
APLP2 is a transmembrane protein of the APP family, involved in cell adhesion, migration, and intracellular signaling. It is processed by ADAM10 and BACE1, and forms complexes with APP and APLP1. APLP2 interacts with adaptors FE65, X11/Mint, and Dab1, linking to integrin beta1 and downstream pathways. Transcriptional regulation by SP1, retinoic acid, and EGF controls APLP2 expression, while it modulates MMP2, MMP9, p53, and BAX activity, and engages MAPK/ERK signaling via FE65 and PSEN1.
In A-549 lung adenocarcinoma cells, APLP2 knockout impairs cell migration and invasion, likely due to disrupted integrin beta1-mediated adhesion and reduced ERK phosphorylation. This phenotype highlights APLP2’s role in metastatic behavior and provides a model to study the interplay between APP-family signaling and oncogenic pathways in a KRAS-mutant background.
The APLP2 Knockout A-549 Polyclonal Cells support functional studies using wound healing, Transwell invasion, and adhesion assays, complemented by phospho-ERK flow cytometry or Western blotting. RT-qPCR enables quantification of downstream targets like MMP9 and BAX. Applications include cancer invasion research, Alzheimer’s disease modeling, and validation of drug candidates targeting APP-family members. For further technical details, please contact Ascent Research.
